Halozyme Therapeutics (HALO)
Halozyme Therapeutics Revenues: 7.440M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HALO Revenues Rankings
| Overall | 10th percentile | 3953 of 4425 |
| Sector | 27th percentile | 339 of 470 in Healthcare |
| Industry | 41st percentile | 77 of 132 in Biotechnology |
HALO Revenues Range, Past 5 Years
| Minimum | 0.7085M | Jun 2007 |
| Maximum | 23.19M | Jun 2011 |
| Average | 5.129M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these HALO related companies
HALO News
http://stks.co/401H follow the smart $$. RJ Kirk own 9.3mil shrs of $HALO & lately a consistent buyer. On last deal he became billionaire!
about 2 days ago by mccartjt
about 2 days ago by mccartjt
http://stks.co/3xM6 Mentions $HALO & $ANGI I'll go with the billionaire RJ Kirk.. Looks like a safe bet to me
about 6 days ago by mccartjt
about 6 days ago by mccartjt
@TradeIdeasQuant $halo believe it was insider buying that brought it to attention last wk & thanks to a twit found here = reason i'm in.
about 8 days ago by Good2go
about 8 days ago by Good2go
$HALO Mentioned more than normal on StockTwits - Currently at 13 x average daily social activity
about 8 days ago by TradeIdeasQuant
about 8 days ago by TradeIdeasQuant
RT @bradloncar some how I don't think that a billionaire is the sucker in the room! LOL $HALO
about 8 days ago by mccartjt
about 8 days ago by mccartjt
@mccartjt Sometimes there is no better medicine for a stock than a well-placed insider buy. $HALO
about 8 days ago by bradloncar
about 8 days ago by bradloncar
RT @bradloncar Good job Randall J Kirk has deep pockets for $HALO.. Nice move so far today!
about 8 days ago by mccartjt
about 8 days ago by mccartjt
EBR: Watchlist/worksheet/4 Trading Ideas: $WMT $HALO $EBAY $UNH http://stks.co/3ulv
about 9 days ago by TheEquitiesRoom
about 9 days ago by TheEquitiesRoom
@strategymizer I picked a circuit breaker. gotta laugh to keep from crying! <<< I have 2 in the last couple months. Invested in $HALO too
about 11 days ago by abrod520
about 11 days ago by abrod520
$HALO Insider Buy: $8M of stock bought by Randal Kirk between May 15, 2012 - May 17, 2012 http://stks.co/3srE
about 12 days ago by MarketBrief
about 12 days ago by MarketBrief
$HALO Insider Buy: $150K of stock bought by Kenneth Kelley on May 14, 2012 http://stks.co/3rRQ
about 13 days ago by MarketBrief
about 13 days ago by MarketBrief
Halozyme Therapeutics to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 09, 8:00AM PR Newswire
May 09, 8:00AM PR Newswire
If current level cannot hold we could see a gap fill $HALO http://chart.ly/bi57d9l
about 23 days ago by CubanMark
about 23 days ago by CubanMark
Wedbush Reiterates an 'Outperform' on Halozyme Therapeutics (HALO); Selloff Over Done, Several Positive Catalysts Ahead
Apr 17, 8:16AM Street Insider
Apr 17, 8:16AM Street Insider
$HALO btw those are buyers in size off the $7.50 dip because the LT is making sure its the real deal and it is $$
about 43 days ago by goingmakai
about 43 days ago by goingmakai
FDA request for data could delay HYQ approval by a year or more. $HALO $BAX http://stks.co/3Mgq
about 43 days ago by abubnic
about 43 days ago by abubnic
UPDATE: FDA Seeks Added Info On $BAX, $HALO HyQ Therapy. http://stks.co/3Mgh
about 43 days ago by abubnic
about 43 days ago by abubnic
106 biotechs in decline today vs 68 in the green. Biggest gain: $IBIO. Biggest loss: $HALO #biotech $$
about 43 days ago by abubnic
about 43 days ago by abubnic
$HALO probably will go down as the most overblown reaction ever I'm sure Kirk bought the dip $$
about 43 days ago by goingmakai
about 43 days ago by goingmakai
BMO Cuts Halozyme (HALO) to Market Perform Following FDA's Request for More Info on HyQ Application
Apr 16, 12:01PM Street Insider
Apr 16, 12:01PM Street Insider
Halozyme Therapeutics, Inc. (HALO) Misses Q4 EPS by 3c; Roche (RHHBY) Triggers $4M Milestone
Mar 09, 7:02AM Street Insider
Mar 09, 7:02AM Street Insider
Halozyme Reports Fourth Quarter and Year End 2011 Financial Results and Provides Guidance for 2012
Mar 09, 7:00AM PR Newswire
Mar 09, 7:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HALO | 8.17 | -0.14 | -1.68% | 931.47M |
| HALL | 7.21 | -0.07 | -0.96% | 140.21M |
| IIIN | 9.78 | +0.00 | +0.00% | 172.23M |
| III | 1.30 | +0.03 | +2.36% | 46.13M |
| IIF | 14.64 | +0.19 | +1.31% | |
| IIC | 15.87 | +0.05 | +0.32% | |
| IHT | 2.03 | +0.00 | +0.00% | 17.19M |
| IHS | 101.70 | -0.32 | -0.31% | 6.650B |
| ICGE | 8.82 | +0.03 | +0.34% | 329.98M |
| ICFI | 22.51 | +0.15 | +0.67% | 442.73M |